Ophysio Inc. — Department of Health and Human Services SBIR Phase I: NIDDK

Description

DESCRIPTION provided by applicant It is believed that emergent stem cell based therapies are destined to replace islet transplantation in the near future The first wave of next generation cell therapeutics for type diabetes T D will likely take the shape of pluripotent stem cell PSC derived pancreatic progenitors PPs that mature into insulin producing cells upon transplantation However for all its promise the success of this approach hinges on the assumption that the microenvironment that leads to effective maturation in a mouse model which is not even diabetic at the time of transplantation in published reports will be the same i human patients with autoimmune diabetes Other considerations such as the safety of partially differentiated PSC derived products and lag time to functional maturation will also have to be addressed The use of fully differentiated insulin producing cells has always been the first choice but the above approach has prevailed owing to the inability of current culture standards at yielding functional cells In collaboration with our partners at the University of Miami Ophysio Inc has successfully developed a platform to aid in the terminal in vitro differentiation of PPs of different origins PSC and native PPs This patented technology is based on the accurate targeting of physiological oxygenation throughout cell aggregates in culture which conventional means of culture fail to achieve Oxygen tension lies at the crossroads of key pancreatic differentiation pathways and its evolution throughout development has been conclusively shown to drive cell fate Here we seek to apply these principles to the terminal maturation of a novel sub population of PPs that our collaborators have described in human non endocrine pancreatic tissue hNEPT which comprises of the pancreas and is routinely discarded after islet isolation This sub population unequivocally identified through i vitro lineage tracing techniques is characterized by its responsiveness to the FDA approved bone morphogenetic protein BMP hNEPT exposure to BMP results in the efficient up to in preliminary data generation of endocrine cells that secrete insulin in response to glucose stimulation in vitro and in vivo at levels that under conditions that will be further explored in this proposal approximate those of human islets BMP responsive PPs from hNEPT represent a valid alternative to PSC for clinical applications as this technology capitalizes on current clinical strategies islet isolation and transplantation for which there ar already well established networks increased safety of adult stem cell products vs PSC derived ones and ease of in vitro expansion using a single FDA approved agent that is already in clinical trials for unrelated conditions Coupled with Ophysioandapos s technology for enhanced in vitro maturation this approach has rapid translational potential for the effective treatment of T D PUBLIC HEALTH RELEVANCE Progress in the efficient generation of insulin producing cells is expected to result in new cell therapies for type diabetes Ophysio Inc has successfully developed a platform to aid in the differentiation of such cells Our patented technology is based on the accurate provision of physiological oxygenation which conventional means of culture cannot achieve Here we seek to apply this principle to the maturation of a novel sub population of pancreatic progenitor cells that our collaborators at the University of Miami have described in human non endocrine pancreatic tissue hNEPT which comprises of the pancreas and is routinely discarded after the insulin producing islets used for islet transplantation are isolate These progenitors are characterized by their responsiveness to BMP an FDA approved agent Coupled with Ophysioandapos s technology for enhanced maturation this approach has rapid translational potential for the effective treatment of T D and as such is highly aligned with the NIH mission